⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of InSysBio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
InSysBio
↗Limassol, Cyprus
InSysBio is a specialized Quantitative Systems Pharmacology (QSP) company that provides mechanistic modeling and simulation services to support drug discovery and development. Founded in 2004, the company helps pharmaceutical and biotech firms make data-driven decisions during critical R&D stages, including dose selection, clinical trial design, and translational medicine.
The company has developed its own proprietary QSP infrastructure, including software tools like the Heta platform, HetaSimulator, and various databases. InSysBio operates internationally with entities in Cyprus and the UK, maintaining a strong focus on academic and industry collaborations to advance systems pharmacology methods.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2004
Ownership:private
Status:operating
FUNDING
Total Raised:$0
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, mAb, Bispecific antibodies, T-cell engagers
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:INSYSBIO CY Ltd, INSYSBIO UK LIMITED
Key Partnerships:BeOne Medicines (Oncology/T-cell engagers), AstraZeneca/MedImmune (Lupus/Anifrolumab), Genmab (Oncology), Discoveric Bio Group (Alzheimer's)
COMPETITION
Position:Niche Player
Competitors:Simulations Plus, Rosa & Co, Metrum Research Group, Certara
LEADERSHIP
Key Executives:
Oleg Demin - CEO & Co-founder
Evgeny Metelkin - Head of Development
Scientific Founders:Oleg Demin, Evgeny Metelkin, Sergey
LINKS
Website:insysbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with InSysBio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.